A. Positive symptoms (e.g., auditory hallucinations, paranoid delusions) B. Negative symptoms (e.g., amotivation, decreased speech productivity) C. Cognitive symptoms (e.g., decreased concentration, processing speed) D. Mood symptoms (e.g., depressed mood, psychomotor retardation) E. Unsure

A. 90% B. 75% C. 50% D. 30% E. Unsure

A. Treatment non-adherence and adverse medication effects B. Comorbid substance abuse and lack of caregiver support C. No comorbid mood disorder and second-generation antipsychotic treatment D. Mental illness stigma and poor therapeutic connection with treatment provider E. Unsure

A. 90% B. 74% C. 68% D. 50% E. Unsure

A. Loxapine B. Fluphenazine C. Perphenazine D. Chlorpromazine E. Unsure

A. Paliperidone B. Aripiprazole C. Ziprasidone D. Risperidone E. Unsure

A. Prior to the first injection of any long-acting injectable antipsychotic, a 0.1-mL test dose should be administered to test for any unknown allergy B. Neuroleptic malignant syndrome is a common adverse effect of both fluphenazine decanoate and haloperidol decanoate C. Patients treated with long-acting aripiprazole injections (monohydrate and lauroxil forms) should be monitored for the development of restlessness, metabolic syndrome, and compulsive behaviors D. Paliperidone palmitate is a cytochrome P450 (CYP) 2D6 substrate and dose reductions should be considered in patients who are also receiving a potent CYP2D6 inhibitor E. Unsure

A. Every state in the United States permits pharmacists to administer LAIAs B. Community pharmacies should provide LAIA patient services in a stigma-free environment with access to a fully private space and the availability of a chaperone C. All available LAIAs require the same method of intramuscular injection and are suspended in a sesame oil vehicle D. Post-injection delirium/sedation syndrome is a risk for all LAIA injections and requires that patients be observed for 3 hours after each injection E. Unsure

A. 234 mg B. 156 mg C. 117 mg D. 78 mg E. Unsure

A. Prior to administering the injection, confirm the patient's identity and current medications B. Educate the patient about aripiprazole's risk for hepatic toxicity, thrombocytopenia, and hyperammonemia C. Administer 400 mg aripiprazole monohydrate intramuscularly (provided there are no interacting medications that should force a re-evaluation of the dose) D. Inform the patient that, after the first intramuscular dose, he needs to continue to take his oral aripiprazole for 14 consecutive days and that he will receive his next injection in 4 weeks E. Unsure